Alternatives to Spinraza (Nusinersen) If You Can't Fill Your Prescription

Spinraza (nusinersen) was the first FDA-approved disease-modifying therapy for spinal muscular atrophy (SMA), but it is not the only option. Since its approval in December 2016, the SMA treatment landscape has expanded significantly. In 2026, there are now multiple approved therapies, each with unique advantages, delivery methods, and eligibility criteria.

This guide covers the main alternatives to Spinraza — what they are, how they work, who they're approved for, and key differences that might influence your care team's recommendation.

Why Patients Look for Alternatives to Spinraza

There are several reasons a patient or family might explore alternatives to Spinraza:

Insurance denial or inability to get prior authorization for Spinraza

Difficulty tolerating or scheduling intrathecal injections every 4 months

Spinal anatomy changes (scoliosis, spinal fusion) making injections difficult or risky

Desire for a one-time or oral treatment option

Plateau in motor function improvement while on current therapy

Alternative #1: Risdiplam (Evrysdi) — Oral, At-Home Treatment

Risdiplam (brand name Evrysdi, manufactured by Genentech/Roche) is an oral liquid medication approved for SMA in patients 2 months and older. It is taken once daily at home, making it one of the most convenient SMA treatment options available.

Like Spinraza, risdiplam is an SMN2 splicing modifier — it works by increasing the production of functional SMN protein from the SMN2 gene. Unlike Spinraza, it is taken orally and works systemically throughout the body, which some researchers believe may offer additional benefits for respiratory and bulbar function.

Key advantages over Spinraza: No injections, no lumbar punctures, no hospital visits for dosing; can be taken at home; approved for SMA Types 1, 2, and 3.

Considerations: Requires daily dosing (vs. every 4 months for Spinraza); some concern about systemic drug exposure; light sensitivity has been reported in adult patients.

Indirect comparisons presented at the 2026 MDA Conference suggested risdiplam may be associated with longer survival and higher rates of motor function improvement compared to nusinersen in children with Type 1 SMA, though no head-to-head trials have been conducted.

Alternative #2: Onasemnogene Abeparvovec (Zolgensma) — One-Time Gene Therapy for Infants

Zolgensma (manufactured by Novartis) is a one-time IV gene therapy approved for children under 2 years of age with SMA. It delivers a functional copy of the SMN1 gene directly to the body using an adeno-associated virus (AAV9) vector, addressing the underlying genetic cause of SMA.

Key advantage: A single infusion — no ongoing dosing required. Real-world data has shown significant motor improvement in infants who received it early.

Limitation: Only approved for children under 2 years old via IV infusion, and at a list price of approximately $2.1 million, it is one of the most expensive drugs ever approved. Pre-existing antibodies to AAV9 may disqualify some patients.

Alternative #3: Itvisma — Intrathecal Gene Therapy for Patients 2 and Older (Approved November 2025)

Itvisma (intrathecal onasemnogene abeparvovec, by Novartis) was FDA-approved in November 2025, expanding gene therapy access to SMA patients aged 2 and older. Like Zolgensma, it is a one-time gene therapy delivering a functional SMN1 gene, but it is administered intrathecally (like Spinraza) rather than intravenously.

Comparative analysis presented at the 2026 MDA Conference suggested that Itvisma achieves motor function improvements comparable to nusinersen and risdiplam in patients with SMA. For patients who have plateaued on Spinraza, switching to Itvisma may offer additional functional gains.

Key advantage: Single administration; designed for broader age groups than IV Zolgensma; may benefit patients who have plateaued on ongoing SMN2-modifying therapies.

Comparing Spinraza vs. Alternatives at a Glance

Spinraza (nusinersen): Intrathecal injection every 4 months; approved all ages; $375,000/year ongoing; 10+ years of real-world safety data

Risdiplam (Evrysdi): Oral liquid daily; approved 2 months and older; ongoing annual costs; convenient at-home dosing

Zolgensma: One-time IV gene therapy; only for children under 2; ~$2.1 million one-time cost

Itvisma: One-time intrathecal gene therapy; approved for patients 2+; newer option with growing real-world data

How to Talk to Your Doctor About Switching

The decision to switch from Spinraza to an alternative (or to start with an alternative instead) should always be made with your SMA specialist. Key questions to discuss include:

Is my current therapy still producing measurable motor function improvement?

What are my SMA type, age, and current functional status, and which therapy is best matched to them?

What are the insurance coverage implications of switching therapies?

Is there a washout period required between stopping Spinraza and starting a new therapy?

medfinder Can Help You Navigate Your Options

Whether you're looking for Spinraza or exploring alternatives, medfinder is a paid service that helps patients find the right pathways to access specialty SMA medications. For more context on how to access Spinraza specifically, see our guide: How to Find Spinraza in Stock Near You.